US FDA warning letter at Indore facility
Indore facility received a warning letter citing Albuterol complaints; resolution timeline uncertain and may impact future approvals.
high · management_commentaryCipla Ltd — Q3 FY24
Cipla delivered a strong Q3 FY24 with revenue of INR 6,544 crore (+14% YoY) and EBITDA margin of 26.3%, driven by market-leading growth in India (+12%), an all-time high US reve...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Goa facility re-inspection uncertainty
Goa facility due for re-inspection; delay or adverse outcome could further delay Abraxane launch.
high · analyst_questionUS generic pricing compression
Pricing environment in US generics is in a downcycle; compression expected to move from 4-6% to 6-8% within a year.
medium · management_commentaryAbraxane launch delay
Abraxane launch via third-party transfer is taking longer; fastest route is from Goa facility, which is subject to FDA inspection.
medium · analyst_question